Safety and Efficacy of Enalapril in Multivalvular Heart Disease with Significant Mitral Stenosis—SCOPE-MS

Safety and Efficacy of Enalapril in Multivalvular Heart Disease with Significant Mitral Stenosis—SCOPE-MS

Angiotensin-converting enzyme inhibitors (ACEI) are often used in preventing and treating heart failure due to regurgitant valve disease. The majority of patients with symptomatic rheumatic heart disease (RHD) have significant mitral stenosis (MS) and are denied ACEI therapy, because of the fear of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Angiology 2005-03, Vol.56 (2), p.151-158
Hauptverfasser: Chockalingam, Anand, Venkatesan, S., Dorairajan, Smrita, Chockalingam, V., Subramaniam, T., Jaganathan, V., Elangovan, S., Alagesan, R., Gnanavelu, G., Arul, A. S.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Aortic Valve Insufficiency - drug therapy
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular system
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug toxicity and drugs side effects treatment
Enalapril - adverse effects
Enalapril - therapeutic use
Exercise Test - drug effects
Female
Follow-Up Studies
Heart Failure - drug therapy
Heart Valve Diseases - drug therapy
Hemodynamics - drug effects
Humans
Hypertension, Pulmonary - drug therapy
Male
Medical sciences
Middle Aged
Mitral Valve Insufficiency - drug therapy
Mitral Valve Stenosis - drug therapy
Pharmacology. Drug treatments
Prospective Studies
Rheumatic Heart Disease - drug therapy
Toxicity: blood
Treatment Outcome
Vascular wall
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Angiotensin-converting enzyme inhibitors (ACEI) are often used in preventing and treating heart failure due to regurgitant valve disease. The majority of patients with symptomatic rheumatic heart disease (RHD) have significant mitral stenosis (MS) and are denied ACEI therapy, because of the fear of hypotension in the presence of fixed obstruction. The authors assessed the safety and efficacy of ACEI in 109 consecutive patients with RHD and with significant mitral stenosis (mitral valve orifice, MVO
ISSN:0003-3197
1940-1574
DOI:10.1177/000331970505600205